- Home
- ITRM vs CASI Comparison
ITRM vs CASI Comparison
Compare ITRM & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRM | CASI |
|---|---|---|
| Founded | 2015 | 1991 |
| Country | Ireland | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 19.7M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ITRM | CASI |
|---|---|---|
| Price | $0.24 | $0.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.00 | $4.00 |
| AVG Volume (30 Days) | ★ 612.9K | 15.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $947.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.74 |
| 52 Week High | $1.49 | $3.08 |
Technical Indicators
Market Signals| Indicator | ITRM | CASI |
|---|---|---|
| Relative Strength Index (RSI) | 38.23 | 20.63 |
| Support Level | N/A | N/A |
| Resistance Level | $0.39 | $1.07 |
| Average True Range (ATR) | 0.03 | 0.10 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 32.07 | 9.49 |
Price Performance
Historical ComparisonAbout ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About CASI CASI Pharmaceuticals Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.